NFKB1 and central nervous system cancer: It can promote glioma growth and temozolomide resistance (27), and also promotes the dissociation of hexokinase 2, a key metabolic enzyme that catalyzes the glycolytic pathway, from the mitochondria by highly activating aerobic glycolysis and binds to an inhibitor of NF-κB, which promotes the expression of PD-L1 and contributes to immune escape from the tumor (28).